RALPH V. FORD, M.D.; BOBBY J. ESTES, M.D.; WILLIAM M. FRASER, M.D.; CARROLL A. HANDLEY, Ph.D.; JOHN H. MOYER, M.D.
Because of the growing number of new agents available for the treatment of hypertensive diseases, the need for simple, efficient and accurate technics for screening these compounds has arisen. The technics should also provide the criteria by which the clinician can determine the efficacy of new antihypertensive agents. We feel that at least three criteria should be fulfilled by any new agent that is to be used for the treatment of hypertension; these are: 1) the drug must be potent in the reduction of abnormally elevated blood pressures; 2) gastrointestinal absorption must be adequate and should be constant so
Learn more about subscription options.
Register Now for a free account.
FORD RV, ESTES BJ, FRASER WM, HANDLEY CA, MOYER JH. LABORATORY AND CLINICAL PHARMACODYNAMICS: OBSERVATIONS ON WIN 8778, WIN 12,512-2, AND WIN 13,596-2, AND AN APPROACH TO STUDYING THESE AND SIMILAR ANTIHYPERTENSIVE AGENTS(LABORATORY AND CLINICAL PHARMACODYNAMICS: OBSERVATIONS ON WIN 8778, WIN 12,512-2, AND WIN 13,596-2, AND AN APPROACH TO STUDYING THESE AND SIMILAR ANTIHYPERTENSIVE AGENTS*). Ann Intern Med. 1957;46:546–567. doi: 10.7326/0003-4819-46-3-546
Download citation file:
Published: Ann Intern Med. 1957;46(3):546-567.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only